Search clinical trials for: Surufatinib/Toripalimab

Total 446 results

Coherus Biosciences, Inc.

Recruiting

Study of CHS-114 in Participants With Advanced Solid Tumors

Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma

United States
China Medical University, China
Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Not yet recruiting

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Gastric Cancer, Metastatic
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Head and Neck Squamous Cell Carcinoma

China
Sun Yat-sen University

Recruiting

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Metastatic | Adenocarcinoma of Small Intestine | Appendix Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Toripalimab for High-risk Locally Advanced Cervical Cancer

Cervical Cancers

China
First Affiliated Hospital of Zhejiang University
Shanghai Longfine Biotechnology Co., Ltd.; TopAlliance

Not yet recruiting

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Triple-negative Breast Cancer

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Sun Yat-sen University
Xiangya Hospital of Central South University; Wuhan University; Zhujiang Hospital and other collaborators

Recruiting

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) (EC-CRT-007)

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Yongchang Zhang

Completed

Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Small Cell Lung Cancer | Chemotherapy Effect | Angiogenesis
Hutchison Medipharma Limited

Recruiting

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Extensive-Stage Small Cell Lung Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 Treatment

China
Sun Yat-sen University

Active, not recruiting

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Nasopharyngeal Carcinoma

China
Xiangya Hospital of Central South University

Recruiting

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

Advanced Biliary Tract Tumors

China
TJ Biopharma Co., Ltd.

Active, not recruiting

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Advanced Solid Tumor

China
Sun Yat-sen University

Recruiting

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Solid Tumor | Intestinal Flora | Immune Checkpoint Inhibitor

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Zhujiang Hospital

Recruiting

Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Urinary Bladder Cancer

China
Peking University Cancer Hospital & Institute

Enrolling by invitation

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Locally Advanced NSCLC

China
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
Sun Yat-sen University

Recruiting

Toripalimab Combined With CAV/IE Regimen

Soft Tissue Sarcoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Sun Yat-sen University

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma

Osteosarcoma

China
Fujian Cancer Hospital
Hunan Cancer Hospital; Wuhan TongJi Hospital

Not yet recruiting

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
Shanghai Jiao Tong University School of Medicine

Completed

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Oral Cancer | Induction Chemotherapy | Programmed Cell Death 1 Inhibitor | Inductive Therapy

China
Peking University Third Hospital

Unknown

Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer. (CCRT+PD-1)

Cervical Cancer

China
Wuhan Union Hospital, China

Not yet recruiting

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC (PC-1)

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy

China
Luo Cong

Completed

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
Shanghai Zhongshan Hospital

Recruiting

Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma (Toripalimab)

Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

Mucosal Melanoma

China
Sun Yat-sen University

Withdrawn

Phase II of Lenvatinib Plus Toripalimab for Advanced HCC

Hepatocellular Carcinoma

China
Bai-Rong Xia

Active, not recruiting

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China

Search clinical trials for: Surufatinib/Toripalimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations